Posts

Showing posts with the label Microscopic Polyangiitis (MPA)

Microscopic Polyangiitis (MPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys, lungs, and peripheral nerves, although muscle involvement with myalgia is rare and typically diagnosed through muscle biopsy specimens showing necrotizing vasculitis. ANCA is present in only 70% of MPA cases at diagnosis, and most instances of limited MPA lack ANCA altogether. This suggests the involvement of other factors in its development, including:   Infectious Causes: There is substantial overlap in the clinical presentation of infectious diseases and MPA, leading to this association. Chronic nasal carriage of Staphylococcus aureus has been implicated in relapsing granulomatosis with polyangiitis (GPA). Drugs: Several drugs, such as hydralazine, thionamides, sulfasalazine, and minocycline, have been linked to the occurrence of ANCA-associated vasculitis. Genetic Factors: genes like HLA-DP, HLA-DR3, and alpha-...

Microscopic Polyangiitis (MPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with antineutrophil cytoplasmic antibody (ANCA) that involves mainly kidneys, lungs and peripheral nerves. MPA can also involve muscles with myalgia, but cases diagnosed by muscle biopsy specimen showing necrotizing vasculitis are rare. MPA can affect people of all ages, but the average age of onset is approximately 50. It affects both men and women, but men may get MPA more often. The disease is more frequent among Caucasians but can affect people of any race or ethnic background. ·        The estimated Microscopic polyangiitis (MPA) prevalence ranges between 2.5 to 3.5 cases per 100,000 persons in the United States, and the incidence ranges between 0.75 to 1.2 cases per 100,000 persons. Thelansis’s “Microscopic Polyangiitis (MPA) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utiliza...

Microscopic Polyangiitis (MPA) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Image
  Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with antineutrophil cytoplasmic antibody (ANCA) that involves mainly kidneys, lungs, and peripheral nerves. MPA can also involve muscles with myalgia, but cases diagnosed by muscle biopsy specimens showing necrotizing vasculitis are rare. MPA can affect people of all ages, but the average age of onset is approximately 50. It affects both men and women, but men may get MPA more often. The disease is more frequent among Caucasians but can affect people of any race or ethnic background. ·        The estimated prevalence ranges between 2.5 to 3.5 cases per 100,000 persons in the United States and the incidence ranges between 0.75 to 1.2 cases per 100,000 persons. The competitive landscape of Microscopic Polyangiitis (MPA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented...